Matt. for joining XXXX you call. quarter conference and Good Thanks our afternoon thank third
quarter million, was total we the in expectations generated line our of which X.X% third XXXX. XXXX, a and decline of $XX.X quarter third with revenue at Looking from the of of reflected
of $XX.X Direct million second in in XX% third X.X% of prior to an reduction approximate of quarter in only quarter versus third representative by period of sales quarter the sales in comparative XXXX the XXXX, the consumer from XXXX the the decreased despite third headcount year.
to headcount We from are offset mostly the reps. productivity the in say sales in by pleased remaining that an increase reduction was
in In their our them continued reps per addition, third are quarter to sales productivity we the we increase and seeing hire XXXX expectations. of new
While the quarter optimistic the direct-to-consumer productivity direct-to-consumer sales our ability and versus third in in of sales we teams. of intake the quarter remain grow these planned XXXX rental based same XXXX in slightly expansion and the improvements on declined in XXXX, to
third to from label business-to-business offset domestic $XX.X national partner, by in orders primarily buys of XXXX providers. million compared of who flat, to quarter private increased orders our decline a other quarter provider Third through sales large from XXXX, were due one
of in the revenue Specifically, this of quarter million provider XXXX, third quarter accounted the down $X.X for XXXX. from $XXX,XXX in third of
concentrators, from solid customers. HME lack capital continue adopting demand expenditure efforts, ongoing portable providers oxygen include of challenges credit facing see the which of are to constraints, these access and available to restructuring spite we In in
will the Additionally, win as reimbursement providers around change we rates. more to with any bidding conservative been pending in and visibility lack who believe investment contracts have in HME to competitive due of XXXX
currency expenditure of constant capital constraints, to a reported in of in as $XX.X International by quarter slowdown XX.X% and sales on third driven XXXX This orders basis due primarily the business-to-business million decreased an a tender quarter on of the was orders compared some quarter and uncertainty, basis France. Britain softness in shortfall Great third XXXX. of to Spain, Third XX.X% and
believe that we lost not to and customers remains in major competition Europe strategy do We have any unchanged. our
will we be in before, said our tender have International countries. are As quarter-to-quarter, we believe resolved, products the can issues that those sales do lumpy as for demand normalize
XXXX, Third third primarily decrease revenue patient. We patients service and quarter patients million as offset the XX,XXX XXXX. declined of partially a to X.X% had quarter third X.X%, of quarter $X.X rental of end due on higher revenue XXXX approximately of service, compared the on of per to by the rental of of
on While to team and continue also these to increased second the the make believe the rental XXXX, quarter the patient team we to of was will intake expanding count in lead team setups increased team. dedicated sales focused of down rental having progress activities. we productivity a slightly, by separate compared rental
initiative we this increase XXXX. As from to in quarter, last revenue contributions mentioned expect rental
to XXXX. XX% quarter quarter the patients in than the the the and both of were units XXXX of GX, Inogen this showing in this for product from of Greater channel third One total demand Transitioning our we launched in third providers. the business-to-business strong Inogen One product shipments GX domestic domestic
Inogen quarter One shipments the believe position. fourth competitive the CE to Inogen and we further We GX applied begun marking XXXX. also international have strengthens of customers One the We our in GX for
One We half the first contract at Czech the also in European Inogen Republic to of manufacturer customers. plan the our XXXX in for of manufacturing GX start
the from I like would market released Medicare full-year CMS comment also recently for the on data XXXX. fee-for-service traditional
limitations certain absence has to we information serve the or the brand information believe that the the long-term as the United in therapy CMS can of such of oxygen market manufacturer States. when auction picture therapy information, a approximate market assemble used to Although
oxygen we in that market estimate long-term XXXX the in dataset, XXXX. from in the grew share the therapy portable on Medicare XX.X% oxygen Based of concentrators XX.X% to
or sales patient private cash not insurance However, include transactions. this estimate does
actual market penetration. may concentrator that conservative of So, data we from the oxygen believe CMS this estimate portable represent a
were a ahead. opportunity modality growing XX% the therapy that be oxygen We on this therapy patients penetration long-term we the our assume in based should full CMS fastest approximately growth and therapy oxygen based long-term estimates served significant of XX% of data POC's to category patients, the by oxygen over be still believe ambulatory still on has POC’s time.
respectively. XX% declined POC comparison, tanks claims XXXX HCPCS Specifically, levels. XX.X% devices KXXXX transfill beneficiary home for and By increased EXXXX above and Code: for oxygen HCPCS by X.X%, Code:
for are patients. We concentrators should to transition oxygen ambulatory that supporting POC’s of vision continued oxygen to the the standard our see pleased long-term therapy care portable become
of submitted to the prior on topic close as XXX XXXX. bids competitive expected the of of XXX On regions XXXX, bidding around bidding official window the we XX, for September
in in expect We expected the acquisition the closed be with to XXXX. announced go January fall pricing summer of contracts effect contract before XXXX August X, XXXX. era, in winners in of announced into XXXX Transitioning as the to
guidance, a contribution in assumed from the in and acquisition direct have business-to-business our We sales minimal XXXX. revenue channels in both consumer to domestic to
side, On the POC with year continue we target XXXX as launch features. to the for non-invasive view product development ventilation an advanced
results. To $XXX $XXX X.X% guidance full-year X.X% total XXXX of revenue close full-year representing to million, XXXX are XXXX, up to maintaining growth million range versus of our we
guidance. to to million, to of the XXXX, growth range of we $XXX a representing revenue our $XXX XX.X% versus midpoint Looking total are XXXX XX.X% guidance providing of
more to order team increases to convert that does approach our HME to rate POC’s reflects in of national their large our to partners the consumer that This provider guidance XXXX. not We this guidance measured discussed also also believe assume expansion. and challenges direct sales the previously
growth in and of today our spite oxygen future to faced stands tanks Inogen from remain will shift more to we benefit Given we challenges the and continue POC's. in the prospects believe XXXX, optimistic about from we
Bauerlein. now our CFO, turn over Ali I that, Ali? call With will to the